Mera Pharmaceuticals EBIT

The latest EBIT for MRPI is $-200K as of October 2011. That compares with $-550K in the prior-year period — up 64.5% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Mera Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, MRPI's EBIT moved from $-550K to $-200K — a 64.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mera Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, MRPI currently prints $-200K for EBIT, while the sector average sits near $130B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Mera Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-200K for MRPI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting MRPI's EBIT ($-200K), review year-over-year change from $-550K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.